2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 225 Pipeline Pharmaceuticals and Vaccines product development pipeline Key NDA New Drug Application USA In-license or other alliance relationship with third party Phase I Evaluation of clinical pharmacology, usually conducted in volunteers S Month of first submission Phase II Determination of dose and initial evaluation of efcacy, conducted in a A Month of first regulatory approval for MAA, this is the first EU small number of patients approval letter Phase III Large comparative study compound versus placebo and or established BLA Biological License Application treatment in patients to establish clinical benefit and safety MAA Marketing Authorisation Application Europe MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Biopharmaceuticals 1995057 tumour necrosis factor receptor-1 TNFR1 acute lung injury I domain antibody 2374697 glucagon like peptide-1 GLP 1 agonist with obesity I half-life improving domain antibody 2661380 immunomodulator solid tumours I 3052230 broblast growth factor ligand trap cancer I otelixizumab CD3 monoclonal antibody s. c. & i. v. rheumatoid arthritis I 249320 myelin-associated glycoprotein monoclonal stroke II antibody 2586881 recombinant human angiotensin converting acute lung injury II enzyme 2 933776 beta amyloid monoclonal antibody geographic retinal atrophy II 1070806 IL18 monoclonal antibody type 2 diabetes II belimumab B lymphocyte stimulator monoclonal idiopathic membranous nephropathy II antibody i. v. belimumab B lymphocyte stimulator monoclonal myaesthenia gravis II antibody i. v. mapatumumab tumor necrosis factorrelated apoptosisadvanced hepatocellular carcinoma II inducing ligand receptor 1 TRAIL-R1 monoclonal antibody mepolizumab IL5 monoclonal antibody nasal polyposis II ofatumumab CD20 human monoclonal antibody s. c. multiple sclerosis II ozanezumab 1223249 neurite outgrowth inhibitor NOGO-A amyotrophic lateral sclerosis II monoclonal antibody Arzerra ofatumumab CD20 human monoclonal antibody chronic lymphocytic leukaemia, first line therapy III & use in relapsed patients Arzerra ofatumumab CD20 human monoclonal antibody diffuse large B cell lymphoma relapsed patients III Arzerra ofatumumab CD20 human monoclonal antibody follicular lymphoma refractory & relapsed patients III Benlysta belimumab B lymphocyte stimulator monoclonal systemic lupus erythematosus III antibody s. c. Benlysta belimumab B lymphocyte stimulator monoclonal vasculitis III antibody i. v. mepolizumab IL5 monoclonal antibody severe asthma III sirukumab IL6 human monoclonal antibody s. c. rheumatoid arthritis III albiglutide GLP 1 agonist type 2 diabetes Submitted S: Jan13 raxibacumab protective antigen inhibitor inhalation anthrax Approved A: Dec12 Cardiovascular & Metabolic 1614235 2330672 sodium dependent glucose transport type 2 diabetes I SGLT1 inhibitor ileal bile acid transport iBAT inhibitor 2849466 selective androgen receptor modulator heart failure I 2890457 endogenous gut peptide stimulator obesity I 1278863 prolyl hydroxylase inhibitor anaemia associated with chronic renal disease II camicinal 962040 motilin receptor agonist delayed gastric emptying II losmapimod p38 kinase inhibitor acute coronary syndrome also COPD II retosiban oxytocin antagonist threatened pre-term labour II ronacaleret calcium receptor antagonist allogeneic haematopoietic stem cell mobilisation II darapladib Lp-PLA2 inhibitor atherosclerosis also diabetic macular oedema III Immuno-inammation 2245840 SIRT1 activator psoriasis II 2586184 Janus kinase 1 JAK1 inhibitor systemic lupus erythematosus & psoriasis II 2941266 CCR1 chemokine receptor antagonist rheumatoid arthritis II vercirnon 1605786 CCR9 chemokine receptor antagonist Crohn's disease III 226 GSK Annual Report 2012 Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Infectious Diseases 2140944 type 2 topoisomerase inhibitor bacterial infections I 2696266 cephalosporin bacterial infections I 1322322 polypeptide deformylase inhibitor bacterial infections II 2336805 hepatitis C virus inhibitor hepatitis C II tafenoquine 8-aminoquinoline Plasmodium vivax malaria II Relenza i. v. zanamivir neuraminidase inhibitor i. v. inuenza III Neurosciences 356278 phoshodiesterase 4 inhibitor Huntington's disease I 2647544 Lp-PLA2 inhibitor Alzheimer's disease I 239512 H3 receptor antagonist multiple sclerosis II 742457 5HT6 antagonist dementia II rategrast dual alpha 4 integrin antagonist VLA4 multiple sclerosis II rilapladib Lp-PLA2 inhibitor Alzheimer's disease II Patrome IPX066 dopamine precursor DOPA decarboxylase Parkinson's disease III N A inhibitor Oncology 525762 bromodomain inhibitor NUT gene midline carcinoma I 2110183 AKT protein kinase inhibitor multiple myeloma I 2256098 focal adhesion kinase inhibitor cancer I 2636771 phosphatidylinositol 3-kinase PI3K inhibitor cancer I trametinib 2141795 MEK1 2 inhibitor AKT protein kinase cancer I inhibitor 2110183 AKT protein kinase inhibitor Langerhan cell histiocytosis II 2110183 AKT protein kinase inhibitor ovarian cancer II dabrafenib BRAF protein kinase inhibitor non-small cell lung cancer II foretinib  transition factor cancer II C-met kinase inhibitor Revolade Promacta thrombopoietin receptor agonist acute myeloid leukaemia II eltrombopag Revolade Promacta thrombopoietin receptor agonist aplastic anaemia II eltrombopag Revolade Promacta thrombopoietin receptor agonist myelodysplastic syndromes II eltrombopag trametinib MEK1 2 inhibitor KRAS mutant non-small cell lung cancer, second II line therapy trametinib dabrafenib MEK1 2 inhibitor BRAF protein kinase colorectal cancer II inhibitor trametinib dabrafenib MEK1 2 inhibitor BRAF protein kinase metastatic melanoma, adjuvant therapy III inhibitor Tyverb Tykerb lapatinib human epidermal growth factor breast cancer, adjuvant therapy III receptor-2 Her2 and epidermal growth factor receptor EGFR dual kinase inhibitor Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor gastric cancer III Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor head & neck squamous cell carcinoma III resectable disease Votrient pazopanib multi-kinase angiogenesis inhibitor ovarian cancer, maintenance therapy III Votrient pazopanib multi-kinase angiogenesis inhibitor renal cell cancer, adjuvant therapy III dabrafenib BRAF protein kinase inhibitor metastatic melanoma Submitted S: Jul12 S: Jul12 trametinib MEK1 2 inhibitor metastatic melanoma Submitted S: Feb13 S: Aug12 trametinib dabrafenib MEK1 2 inhibitor BRAF protein kinase metastatic melanoma Submitted S: Feb13 inhibitor Tyverb Tykerb lapatinib Her2 and EGFR dual kinase inhibitor metastatic breast cancer, in combination with Submitted S: Feb12 trastuzumab Votrient pazopanib multi-kinase angiogenesis inhibitor sarcoma Approved A: Aug12 A: Apr12 Revolade Promacta thrombopoietin receptor agonist hepatitis C induced thrombocytopaenia Approved S: May12 A: Nov12 eltrombopag Ophthalmology darapladib Lp-PLA2 inhibitor diabetic macular oedema also atherosclerosis II 2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 227 Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory 1325756 CXCR2 chemokine receptor antagonist COPD I 2256294 soluble epoxide hydrolase inhibitor COPD I 2269557 phosphoinositide 3 kinase inhibitor asthma & COPD I 2339345 sodium channel blocker cough I uticasone furoate glucocorticoid agonist long-acting beta2 COPD I 685698 vilanterol agonist muscarinic acetylcholine umeclidinium 573719 antagonist muscarinic antagonist, beta2 agonist COPD 961081 II 2190915  protein FLAP asthma II inhibitor 2245035 toll-like receptor 7 agonist asthma II dilmapimod p38 kinase inhibitor i. v. acute lung injury & acute respiratory distress syndrome II uticasone furoate glucocorticoid agonist muscarinic asthma II 685698 acetylcholine antagonist umeclidinium 573719 losmapimod p38 kinase inhibitor oral COPD also acute coronary syndrome II uticasone furoate glucocorticoid agonist asthma III 685698 Relvar Breo long-acting beta2 agonist glucocorticoid COPD mortality outcomes III vilanterol agonist uticasone furoate umeclidinium 573719 muscarinic acetylcholine antagonist COPD III vilanterol long-acting beta2 agonist COPD III Relvar Breo long-acting beta2 agonist glucocorticoid asthma Submitted S: Jun12 vilanterol agonist uticasone furoate Relvar Breo long-acting beta2 agonist glucocorticoid COPD Submitted S: Jun12 S: Jul12 vilanterol agonist uticasone furoate Anoro umeclidinium muscarinic acetylcholine antagonist COPD Submitted S: Jan13 S: Dec12 vilanterol long-acting beta2 agonist Paediatric Vaccines S. pneumoniae paediatric recombinant conjugated Streptococcus pneumoniae disease prophylaxis II next generation MMR live attenuated measles, mumps, rubella prophylaxis III USA A: Nov97 Mosquirix Malaria RTS, S recombinant malaria prophylaxis Plasmodium falciparum III N A MenHibrix Hib-MenCY-TT conjugated Neisseria meningitis groups C & Y & Haemophilus Approved N A A: Jun12 inuenzae type b disease prophylaxis Nimenrix MenACWY-TT conjugated Neisseria meningitis groups A, C, W & Y disease prophylaxis Approved A: Apr12 II, USA Other Vaccines HIV recombinant HIV disease prophylaxis I NTHi recombinant non-typeable Haemophilus inuenzae prophylaxis I Staphylococcus Aureus recombinant conjugated Staphylococcus aureus prophylaxis I HIV recombinant HIV disease immunotherapy II Tuberculosis recombinant tuberculosis prophylaxis II Zoster recombinant Herpes Zoster prophylaxis III Flu prepandemic H5N1 inactivated split monovalent Quebec pre-pandemic & pandemic inuenza prophylaxis Submitted N A S: Feb12 Flu vaccine inactivated split quadrivalent seasonal inuenza prophylaxis Approved S: Mar12 A: Dec12 Antigen-Specic Cancer Immunotherapeutic PRAME recombinant treatment of resectable non-small cell lung cancer I immunotherapeutic WT1 recombinant treatment of breast cancer I immunotherapeutic MAGE-A3 recombinant treatment of bladder cancer II immunotherapeutic MAGE-A3 recombinant treatment of melanoma III immunotherapeutic MAGE-A3 recombinant treatment of non-small cell lung cancer III immunotherapeutic 228 GSK Annual Report 2012 Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Rare Diseases migalastat HCl ERT pharmacological chaperone enzyme Fabry disease II replacement therapy ERT drisapersen 2402968 antisense oligonucleotide Duchenne muscular dystrophy III 2696273 ex-vivo stem cell gene therapy adenosine deaminase severe combined immune III deficiency ADA-SCID migalastat HCl pharmacological chaperone Fabry disease III Stiefel late-stage assets only 2894512 non-steroidal anti-inammatory atopic dermatitis II alitretinoin retinoic acid receptor modulator chronic hand eczema III N A Duac low dose clindamycin benzoyl peroxide gel acne vulgaris Submitted S: Nov11 S: Nov10 Fabior tazarotene foam retinoid foam acne vulgaris Approved N A A: May12 Sorilux vitamin D3 analog scalp psoriasis Approved N A A: Sep12 HIV ViiV Healthcare 1265744 HIV integrase inhibitor long-acting HIV infections II parenteral formulation dolutegravir abacavir HIV integrase inhibitor reverse transcriptase HIV infections III sulphate lamivudine inhibitors xed dose combination dolutegravir HIV integrase inhibitor HIV infections Submitted S: Dec12 S: Dec12 Brand names appearing in italics are trademarks either owned by and or licensed to GlaxoSmithKline or associated companies.
Option-based alliances with third parties that include assets in Phase I or later development: Company Disease Area Phase Cancer Research UK I cancer ChemoCentryx II inammatory disease Dynavax Technologies II cutaneous & systemic lupus erythematosus ISIS Pharmaceuticals II III  amyloidosis OncoMed Pharmaceuticals I oncology Prosensa Therapeutics neuroscience II Ranbaxy Laboratories respiratory II Telethon Institute for Gene Therapy stem cell gene therapy II Afris Alzheimers disease treatment vaccine II CCX168 Two assets
